Testing for Sars-CoV-2 in resource-limited settings

Early diagnosis of SARS-CoV-2 is fundamental to reduce the risk of community transmission and mortality, as well as public sector expenditures. Three years after the onset of the SARS-CoV-2 pandemic, there are still gaps on what is known regarding costs and cost drivers for the major diagnostic testing strategies in low- middle-income countries (LMICs). This study aimed to estimate the cost of SARS-CoV-2 diagnosis of symptomatic suspected patients by reverse transcription polymerase chain reaction (RT-PCR) and antigen rapid diagnostic tests (Ag-RDT) in Mozambique. We conducted a retrospective cost analysis from the provider’s perspective using a bottom-up, micro-costing approach, and compared the direct costs of two nasopharyngeal Ag-RDTs (Panbio and Standard Q) against the costs of three nasal Ag-RDTs (Panbio, COVIOS and LumiraDx), and RT-PCR. The study was undertaken from November 2020 to December 2021 in the country’s capital city Maputo, in four healthcare facilities at primary, secondary and tertiary levels of care, and at one reference laboratory. All the resources necessary for RT-PCR and Ag-RDT tests were identified, quantified, valued, and the unit costs per test and per facility were estimated. Our findings show that the mean unit cost of SARS-CoV-2 diagnosis by nasopharyngeal Ag-RDTs was MZN 728.00 (USD 11.90, at 2020 exchange rates) for Panbio and MZN 728.00 (USD 11.90) for Standard Q. For diagnosis by nasal Ag-RDTs, Panbio was MZN 547.00 (USD 8.90), COVIOS was MZN 768.00 (USD 12.50), and LumiraDx was MZN 798.00 (USD 13.00). Medical supplies expenditures represented the main driver of the final cost (>50%), followed by personnel and overhead costs (mean 15% for each). The mean unit cost regardless of the type of Ag-RDT was MZN 714.00 (USD 11.60). Diagnosis by RT-PCR cost MZN 2,414 (USD 39.00) per test. Our sensitivity analysis suggests that focussing on reducing medical supplies costs would be the most cost-saving strategy for governments in LMICs, particularly as international prices decrease. The cost of SARS-CoV-2 diagnosis using Ag-RDTs was three times lower than RT-PCR testing. Governments in LMICs can include cost-efficient Ag-RDTs in their screening strategies, or RT-PCR if international costs of such supplies decrease further in the future. Additional analyses are recommended as the costs of testing can be influenced by the sample referral system

2019-20 coronavirus outbreak · Biology · Computational biology · Diagnostic test · Computer Science · COVID-19 diagnosis using AI · Medicine · SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · Emergency Medicine · Internal Medicine · Virology

• Provider costs of professional Covid-19 rapid antigen testing in low-income settings

  Open Access•Collin Mangenah, Lucky G Ngwira et al.•PLOS Global Public Health•2025

  Add to list

• Methods for the Economic Evaluation of Health Care Programmes

  Bernie J O'Brien, Michael E Drummond et al.•Methods for the economic…•2005

  Add to list

• Step-by-step guideline for disease-specific costing studies in low- and middle-income countries

  Open Access•Marleen Elisabeth Hendriks, Piyali Kundu et al.•Global Health Action•2014

  Add to list

• Estimating the cost and cost-effectiveness for obstetric fistula repair in hospitals in Uganda

  Open Access•Isabella Epiu, Godfrey Alia et al.•Health Policy and Planning•2018

  Add to list